HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya SHARe Symposium 2019, with the theme: "Bridging the Gap between research and Health care Delivery". See you there!… https://t.co/Y0E6pXekwL
NIMRMbeya The site Initiation of the EDCTP funded LIFE project in Tanzania: The study team at the Tanzanian National Institut… https://t.co/FfVS2YGy2G
NIMRMbeya Site initiation visit for Holistic Approach to Unravel Antibacterial Resistance in East Africa #HATUA study at NIMR… https://t.co/ciG1psDCu0
NIMRMbeya RT @MHRPInfo: This week MHRP @wrair is participating in the annual HVTN meeting in Washington, D.C. Here, Deputy Director LTC Julie Ake tal…
© 2017 NIMR - Mbeya Medical Research Center